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SURVIVAL AND NURSING HOME FREE 
SURVIVAL (NHFS) OF AD PATIENTS
Wu EQ, Hay J
University of Southern California, Los Angeles, CA, USA
OBJECTIVE: To model survival and NHFS of Alzheimer
Disease (AD) patients. To justify the Mini-Mental Status
Examination (MMSE) score as an important predictor of
patient survival and nursing home utilization. METH-
ODS: Survival models were applied to analyze the Mini-
mum Uniform Data Set (MUDS), developed and main-
tained by Alzheimer Research Centers of California
(ARCC). The study sample included 3150 AD patients,
who enrolled in ARCC between Oct. 1992 and Jan.
1999. Cox regression models with and without time-
dependent covariates were used in the analysis. Results
were adjusted by comorbidities. RESULTS: The MMSE
score was shown to be a strong predictor of both AD pa-
tients’ survival and NHFS. One-unit increase of MMSE
score (on a 30-point scale) corresponds to a 5.5% hazard
reduction. That is to say, if a patient’s 5-year survival
probability is 0.500, with his MMSE score increased by
one unit, the probability will be increased to 0.520. One
unit increase of MMSE also corresponds to 6.4% hazard
reduction in future nursing home utilization, which
means a NHFS probability of 0.500 will be increased to
0.523. Female, black, and Hispanic had higher survival
probability. Older age, longer education, and history of
major psychosis in patient’s primary relatives caused
lower survival rate. Marriage and female gender in-
creased NHFS; high value in Body mass index decreased
NHFS. All the above results were significant at 0.01 or
0.05 level. CONCLUSIONS: The study showed MMSE
was a strong predictor of patient survival and NHFS.
Further study should be conducted to explore the possi-
bility that MMSE score can be used as a clinical indicator
for treating AD patients. It is also interesting that, older
age doesn’t have significant impact on NHFS although it
is a strong predictor of survival. On the other hand, mar-
riage has a significant impact on NHFS, but not on sur-
vival.
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OBJECTIVE: A French national epidemiological study
on migraine was presented 10 years ago at the Migraine
trust. It was the first study to cover an entire country
(HENRY P. et al.: Migraine prevalence in France. In New
advances in headache research: 2. Ed. Clifford Rose 1991
Smith Gordon—pp. : 11–14). This study has provided
also data on the burden of migraine in terms of its eco-
nomic and social impact. We would like today to update
the data. METHODS: 1486 persons, aged over 15 and
suffering from headaches were randomly selected from a
large representative sample of the French population.
They were asked to complete a questionnaire, which al-
lowed discriminating sufferers of migraine according to
IHS criteria. RESULTS: Among the 1486 headache suf-
ferers, we find 880 migrainous people (1-1, 1-2 and 1-7
IHS criteria), 454 without migrainous headache and 152
with chronic daily headache. If we compare the results of
the certain migraine group (1-1 and 1-2 IHS) we find that
they are identical (8,1% (1989) versus 8,2% (1999)).
However, if we include the migrainous disorder group
fulfilling all criteria but one (1-7 IHS), the prevalence rate
for migraine headache in France between 1989 and 1999
seems to show a clear increase, rising from 12,1% to
17,3% because of less restrictive criteria than those ap-
plied ten years ago. Regarding the prevalence in general
population for chronic daily headache the rate is around
3% with 1,8% for men and 3,9% for women in 1999.
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In a previous study, sumatriptan therapy was associated
with improvements in Health Related Quality of Life
(HRQoL). Using the same population, the present study
explores additional changes in HRQoL between patients
who did and did not receive migraine prophylaxis medi-
cation. OBJECTIVES: To compare the difference in
HRQoL of migraineurs who did and did not receive mi-
graine prophylactic medication. METHODS: A retro-
spective database analysis was conducted using phar-
macy claims and HRQoL data. Study patients were from
a managed care organization, were diagnosed with mi-
graine, and were initiated on sumatriptan (baseline). The
SF-36 and Migraine-Specific Quality of Life Question-
naire-Version 1.0 (MSQ) surveys were administered at
baseline, 3 and 6 months after initiation of sumatriptan.
Patients were identified for the prophylaxis group if they
received any medication from a previously developed list
of possible migraine prophylaxis medications: 1) within
30 days prior to baseline and 2) at least 4 out of the 6
months after baseline. A two-way repeated measures
ANOVA was performed comparing differences in HRQoL
between the groups from baseline to 6 months. RESULTS:
Of 178 patients, 40 were in the prophylaxis group and
138 in the non-prophylaxis group. Statistically significant
increases were found in the MSQ Role Function-Restric-
